Preferred Label : Anti-HLA-G/CD3 Bispecific Antibody RO7515629;
NCIt synonyms : TCB RO7515629; HLA-G-TCB RG6353; TCE RO7515629; HLA-G TCB RO7515629; Anti-HLA-G T-cell Engager RO7515629; CD3-binding T-cell Engager RO7515629; T-cell Bispecific Antibody RO7515629;
NCIt definition : A bispecific antibody targeting the tumor-associated antigen (TAA) histocompatibility
antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on
T-lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic
activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody RO7515629
targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HLA-G found on
HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing
tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor
cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface,
is expressed across multiple tumor cell types and plays a key role in cancer immune
evasion. It inhibits the immune responses by binding to its inhibitory receptors on
a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes,
and dendritic cells (DCs).;
Molecule name : RO 7515629; RO-7515629; RG-6353; RG 6353;
NCI Metathesaurus CUI : CL1928371;
Origin ID : C205680;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
